Illumina, Inc. DNA Screen For Down Syndrome Found More Accurate

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Illumina Inc. (ILMN)’s genetic screening for Down syndrome and Edwards syndrome provided a more accurate diagnosis than traditional techniques in a company-funded study. The technology, called cell-free DNA testing, turned up significantly fewer false positives in a study of 1,914 women than standard serum screening, according to a paper released yesterday by the New England Journal of Medicine. The study may support expansion of the testing to expectant mothers beyond only those considered at high risk for having babies with Down and Edwards syndromes, chromosomal conditions that lead to developmental issues.

Help employers find you! Check out all the jobs and post your resume.

Back to news